Atlanta 12/27/2013 6:26:29 AM
News / Stocks

MissionIR News – Seeking Alpha Publishes Article Featuring CytRx Corp.

MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical company developing and commercializing the candidates in its oncology-focused development pipeline. The Company’s lead product is aldoxorubicin, an improved formulation of the widely used chemotherapy agent, doxorubicin.  

In company news, Seeking Alpha has published an article recapping the Company’s recent phase 2b clinical trial, a head-to-head clinical comparison of aldoxorubicin vs. doxorubicin in which aldoxorubicin demonstrated superiority as a first-line therapy for patients with soft tissue sarcoma.

The article, entitled “CytRx Corporation's Aldoxorubicin Looks Like A Winner,” can be found here:

“If trials continue as successfully as they have, Investors should see aldoxorubicin take the place of doxorubicin. CytRx Corporation will also find an immediate market with a monstrous revenue stream,” writes U.S. Biotech Investor.

The article also highlights several supporting reasons the writer is bullish on CytRx stock, such as the Company’s financial position; option rights to the protein-binding platform technology that serves as the linker with doxorubicin; and key quotes from the Company’s CEO Steve Kriegsman.

For more information on CytRx Corp., visit   

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.